NCT06211413
Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors
Enrolling by Invitation
Not specifiedAges 22+ObservationalAbramson Cancer Center at Penn MedicineInvestigator-initiated
~50 participants
Updated 2026-03-23 on ClinicalTrials.gov
What's tested:no intervention
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of hypertension
Measured over 6 months
Conditions
NCT06211413
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvaniano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Michael Fradley, MD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age ≥22
Initiation of BTK inhibitor (acalabrutinib or zanubrutinib) with or without other concurrent systemic therapy as front line or relapsed/refractory therapy for chronic lymphocytic leukemia, ordered by treating oncologist per standard of care
Normal sinus rhythm at the time of consent
Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).
Exclusion
Current use of a class IC or III antiarrhythmic medication
AF or other arrhythmia at the time of consent
Uncontrolled hypertension (≥140/90mmHg) at the time of consent
Inability to provide informed consent
Inability to wear a watch
Arm circumference too small (\< 9 in) or arm circumference too large (\> 14.5in.) to use the QardioArm cuff
Expected survival less than one year.
Pregnancy at time of consent
Lack of access to a personal Apple iPhone. If the patient does not have an Apple iPhone, but another member of the patient's household has an iPhone, the patient may still be enrolled as long as there is no other Apple Watch paired with the phone.
What this trial measures
- Incidence of hypertension6 months
New onset or worsening hypertension recorded on home blood pressure monitoring